Double immunotherapy attack on tough lymphoma shows promise
NCT ID NCT07326371
First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests a new combination of two powerful immune-based treatments—glofitamab and CAR-T therapy—for people with high-risk large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the combination can shrink or eliminate tumors more effectively than either treatment alone. About 24 participants will be enrolled at one center, and the main measure of success is the complete response rate (no detectable cancer).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.